Syneron Medical Ltd (ELOS) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Syneron Medical Reports Second Quarter 2016 Revenue of $75.0 Million and Non-GAAP EPS of $0.09
August 4, 2016 7:01 AM EDTIRVINE, Calif., Aug. 4, 2016 /PRNewswire/ --Â Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced financial results for the three month period ended June 30, 2016.
Second Quarter 2016 Non-GAAP2 Financial Highlights:
Revenue of $75.0 million, up 2.0% year-over-year, with 11.5% international growth and a 14% decline in North America Emerging products revenue, which represent the Company's strategic growth drivers, grew 46% year-over-year, primarily driven by the Body Shaping portfolio Total Body Shaping revenue of $17.3 million grew 66% year-over-year Non-GAAP net income of $3.2 million, or $0.09 per... More